Clinical Trials Logo

Clinical Trial Summary

Spinal metastases account for 60% of all malignant bone metastases and represent a medically important treatment goal. For patients with malignant tumors diagnosed at this stage, performing En bloc spondylectomy with wide margin of resection facilitate the improvement in quality of life including ambulatory ability, daily activities independence and attenuation of bone pain. However, En bloc spondylectomy is a major operation with long operation time and frequent hemodynamic instability during the operation. Therefore, the anesthetic care plays an important role and an enhanced recovery after surgery (ERAS) is the goal. For the ERAS anesthesia protocol for En bloc spondylectomy, we propose two major components to achieve this goal: (1) an encephalographic spectrum guided multimodal anesthesia combined with ultrasound-guided nerve block and (2) the advanced machine-learning algorithm index, namely the hypotension predictive index (HPI) guided hemodynamic protocol.


Clinical Trial Description

The anesthetic protocol comprises of two major proposed components to enhanced recovery after spine cancer total en bloc resection. First, a multimodal general anesthesia consisting of GABAnergic hypnotic agent (propofol or sevoflurane), ketamine and dexmedetomidine was conducted by using the encephalographic density spectrum array. In addition, ultrasound-guided erector spinae plane block is applied. These techniques potentially prevent anesthesia induced delirium and may profoundly improve postoperative analgesic quality. Second, advanced hemodynamic monitoring device, namely the hypotensio predictive index, will be used for prevention of intraoperative hypotension and facilitate precise transfusion protocol. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05427825
Study type Interventional
Source National Taiwan University Hospital
Contact Chun-Yu Wu
Phone +886-9-72653376
Email b001089018@tmu.edu.tw
Status Recruiting
Phase N/A
Start date July 2022
Completion date January 2024

See also
  Status Clinical Trial Phase
Recruiting NCT05115331 - Palliative UNConventional Hypofractionation Trial for Metastatic Bone Disease Phase 3
Recruiting NCT04634227 - Gemcitabine Plus Ascorbate for Sarcoma in Adults (Pilot) Early Phase 1
Completed NCT04660591 - Length of the Femoral Stem in Arthroplasty Done for Patients With Proximal Femoral Metastatic Lesion N/A
Completed NCT05110430 - Automated Detection of Metastatic Bone Disease on Bone Scintigraphy Scans
Not yet recruiting NCT04364724 - CTFEA Myeloma Study
Terminated NCT03468075 - Gemcitabine Plus Ascorbate for Sarcoma in Adults Phase 2
Active, not recruiting NCT03963531 - Patterns of Care and Outcomes in Patients With Metastatic Bone Tumors (METABONE)
Recruiting NCT05058014 - Skeletal Metastasis Registry